Catheter Precision, Inc. announced on January 15, 2025, that it has entered into a definitive agreement to acquire PeriKard, LLC. This transaction involves the issuance of restricted VTAK common stock.
The acquisition is for 100% of the LLC interests in PeriKard. This strategic move aims to integrate PeriKard's technology into Catheter Precision's portfolio of electrophysiology products.
The acquisition of PeriKard, LLC represents an expansion of Catheter Precision's focus within the cardiac market. This agreement is a step towards broadening the company's offerings and addressing additional needs in cardiac care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.